Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

Virus reactivation in acute and long COVID-19

Maguire C, Chen J, Rouphael N, Morse BA, Hoch A, Pickering H, Phan HV, Glascock A, Chu V, Dandekar R; IMPACC Network; Corry D, Kheradmand[...]

The future of home oxygen therapy

Holland AE, Krishnan JA, Lacasse Y, Gomes H, Björklund F, Casaburi R, de Andrade J, Eakin MN, Hui D, Jacobs SS, Kawachi S, Khor YH,[...]

Variation in Hospital Visiting Hour Policies in Acute Care Facilities in Four U.S. States: An Exploratory Cross-Sectional Analysis

Garcia CY, Chou C, Caso E, Hudspeth JC, Allan-Blitz LT. Variation in Hospital Visiting Hour Policies in Acute Care Facilities in Four U.S. States: An[...]